Compare Mesoblast Limited (MESO) vs SAP SE (SAP) Price & Performance

MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.

Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.

SAP trades at $158.40, down 0.4% today, with a neutral technical signal and bearish moving averages. The company reported strong Q1 2026 earnings of $2.01 per share, beating estimates, and maintains robust profitability with a 19.58% net income margin. Recent news highlights SAP's focus on AI investments and cost discipline, while EU antitrust concerns were resolved with concessions. Cash flow from operations remains strong at $9.16 billion for 2025, though net cash flow was negative $1.39 billion due to financing activities.

SAP presents a favorable risk-reward profile with a consensus price target of $222.33, implying significant upside. Analyst sentiment is bullish with 53.49% buy ratings. Key risks include competitive pressures in enterprise software and macroeconomic sensitivity. The stock's current valuation at a P/E of 22.38 offers a discount to growth prospects, supported by consistent earnings beats and strategic AI initiatives.